4-Nov-2025 6:00 AM CST - Business Wire United Therapeutics Corporation to Present at Upcoming Investor Conferences United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions at two upcoming investor conferences. Patrick Poisson, Executive Vice President, Strategic Development, will present at the UBS Global Healthcare Conference in Palm Beach, Florida on Monday, November 10, 2025, from 9:30 a.m. to 10:0
29-Oct-2025 5:30 AM CST - Business Wire United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced record financial results for the quarter ended September 30, 2025, driven by continued year-over-year revenue growth in key products such as Tyvaso and Orenitram. Total revenues in the third quarter of 2025 grew seven percent year-over-year to $799.5 million, compared to $748.9 million in the third quarter of 2024. "Our commercial an
15-Oct-2025 6:00 AM CST - Business Wire United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025 United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2025 financial results before the market opens on Wednesday, October 29, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, October 29, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via
19-Sep-2025 6:00 AM CST - Business Wire United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso in Idiopathic Pulmonary Fibrosis United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will host a webcast to review data from the successful TETON-2 pivotal study evaluating the use of nebulized Tyvaso (treprostinil) Inhalation Solution for the treatment of idiopathic pulmonary fibrosis (IPF) on Sunday, September 28, 2025, at 12:30 p.m. Eastern Time. During the webcast, Steven D. Nathan, M.D., Schar Chair, Advanced Lung Disease and Lung Tran
16-Sep-2025 6:00 AM CST - Business Wire United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare Forum United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer, will provide an overview and update on the company during a fireside chat session at the Bernstein 2nd Annual Healthcare Forum in New York. The session will take place on Tuesday, September 23, 2025, from 1:10 p.m. to 1:50 p.m., Eastern Standard Time, and can be ac
29-Aug-2025 6:00 AM CST - Business Wire United Therapeutics Corporation to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update on the companys operations during a fireside chat session at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. The session will take place on Monday, September 8, 2025, from 3:20 p.m. to 3:55 p.m., Eastern Standard Ti
30-Jul-2025 5:30 AM CST - Business Wire United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced record financial results for the quarter ended June 30, 2025, driven by continued double-digit year-over-year revenue growth in key products such as Tyvaso DPI, Nebulized Tyvaso, Orenitram, and Unituxin. Total revenues in the second quarter of 2025 grew 12 percent year-over-year to a record $798.6 million, compared to $714.9 million in
16-Jul-2025 6:00 AM CST - Business Wire United Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025 United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2025 financial results before the market opens on Wednesday, July 30, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, July 30, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via Unite
30-Apr-2025 5:30 AM CST - Business Wire United Therapeutics Corporation Reports First Quarter 2025 Financial Results United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2025. Total revenues in the first quarter of 2025 grew 17 percent year-over-year to $794.4 million, compared to $677.7 million in the first quarter of 2024. 2025 is off to a tremendous start as we reported yet another quarter of record revenue, said Martine Rothblatt, Ph.D., Chair
Latest UTHR Trades by Congress Members
31-OCT-2025 - Lisa McClain, MI (District 9) sold between $1,001 and $15,000.
4-Nov-2025 6:00 AM CST - Business Wire United Therapeutics Corporation to Present at Upcoming Investor Conferences United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions at two upcoming investor conferences. Patrick Poisson, Executive Vice President, Strategic Development, will present at the UBS Global Healthcare Conference in Palm Beach, Florida on Monday, November 10, 2025, from 9:30 a.m. to 10:0
29-Oct-2025 5:30 AM CST - Business Wire United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced record financial results for the quarter ended September 30, 2025, driven by continued year-over-year revenue growth in key products such as Tyvaso and Orenitram. Total revenues in the third quarter of 2025 grew seven percent year-over-year to $799.5 million, compared to $748.9 million in the third quarter of 2024. "Our commercial an
15-Oct-2025 6:00 AM CST - Business Wire United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025 United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2025 financial results before the market opens on Wednesday, October 29, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, October 29, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via
19-Sep-2025 6:00 AM CST - Business Wire United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso in Idiopathic Pulmonary Fibrosis United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will host a webcast to review data from the successful TETON-2 pivotal study evaluating the use of nebulized Tyvaso (treprostinil) Inhalation Solution for the treatment of idiopathic pulmonary fibrosis (IPF) on Sunday, September 28, 2025, at 12:30 p.m. Eastern Time. During the webcast, Steven D. Nathan, M.D., Schar Chair, Advanced Lung Disease and Lung Tran
16-Sep-2025 6:00 AM CST - Business Wire United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare Forum United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer, will provide an overview and update on the company during a fireside chat session at the Bernstein 2nd Annual Healthcare Forum in New York. The session will take place on Tuesday, September 23, 2025, from 1:10 p.m. to 1:50 p.m., Eastern Standard Time, and can be ac
29-Aug-2025 6:00 AM CST - Business Wire United Therapeutics Corporation to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update on the companys operations during a fireside chat session at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. The session will take place on Monday, September 8, 2025, from 3:20 p.m. to 3:55 p.m., Eastern Standard Ti
30-Jul-2025 5:30 AM CST - Business Wire United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced record financial results for the quarter ended June 30, 2025, driven by continued double-digit year-over-year revenue growth in key products such as Tyvaso DPI, Nebulized Tyvaso, Orenitram, and Unituxin. Total revenues in the second quarter of 2025 grew 12 percent year-over-year to a record $798.6 million, compared to $714.9 million in
16-Jul-2025 6:00 AM CST - Business Wire United Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025 United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2025 financial results before the market opens on Wednesday, July 30, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, July 30, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via Unite
30-Apr-2025 5:30 AM CST - Business Wire United Therapeutics Corporation Reports First Quarter 2025 Financial Results United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2025. Total revenues in the first quarter of 2025 grew 17 percent year-over-year to $794.4 million, compared to $677.7 million in the first quarter of 2024. 2025 is off to a tremendous start as we reported yet another quarter of record revenue, said Martine Rothblatt, Ph.D., Chair
